ACTUAL FACT Based VRX's #'s validated by their 10K which VRX always tries to lead investors away from
Taken straight from VRX's and AGN's 2013 10K:
-VRX's Operating (Loss) / Income was ($410MM) in 2013, $80MM in 2012, and $300MM in 2011. Comparatively, AGN's Operating Income was $1.809B in 2013, $1.611B in 2012, and $1.375B in 2011.
-VRX's Net (Loss) / Income was ($864MM) in 2013, ($116MM) in 2012, and $160MM in 2011 (even with their lower tax rate) compared to AGN's Net Income of $989MM in 2013, $1.103B in 2012 and $938MM in 2013 (a number you know Allergan actively manages down to avoid paying their higher tax rate).
-VRX's Accumulated Deficit was a whopping ($3.279B) in 2013 and ($2.371B) compared to AGN's Retained Earnings of $4,647B in 2013 and $3.832B in 2012.
Meanwhile, here are actual AGN #'S from their latest quarter, and is why they are rated a Buy:
'■The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 1958.4% when compared to the same quarter one year prior, rising from $12.50 million to $257.30 million.'
VRX could NEVER EVER come close to these numbers and never will. VRX is a sham.
Thanks for the data. I see a positive trend for VRX and a negative trend for AGN. I might need glasses. One company is on the up and up(VRX) and the other(AGN) appears to be taking a hit each quarter, but still a good company that will get taken over by VRX. Deal with it.
Their 'actual fact based' (such a joke coming from Valeant) #'s from their 10K do not get hardly the spotlight they deserve in article after article. Of course Valeant will have you look at anything else other than their actual performance.